Fresenius Medical Care : Q2 2018: Strong reported EBIT thanks to divestment of Sound
>Q2 2018 results: Reported EBIT above consensus; adjusted EBIT misses our estimate - FMC posted its Q2 2018 results today (31 July). Reported revenue was € 4,214m, bang in line with expectations (Oddo BHFe: € 4,208m Vara consensus/cs: € 4,212m). (Note all consensus references below refer to Vara consensus.) In constant currencies (cc) revenue increased +5% yoy. Reported EBIT came in at € 1,401m, beating our estimate (€ 1,200m) and consensus (€ 1,272m). The beat ...RegistrarFresenius Medical Care is a kidney dialysis company, operating in both the field of dialysis services and the field of dialysis products for the treatment of end-stage renal disease (ESRD). Co.'s dialysis business is vertically integrated, providing dialysis treatment at dialysis clinics it owns or operates and supplying these clinics with a range of products. In addition, Co. sells dialysis products to other dialysis service providers. In the U.S.A., Co. also provides inpatient dialysis services and other services under contract to hospitals. Co. provides patient services, including renal pharmaceutical products and in the U.S.A., laboratory services.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.